High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease
Clinical Gastroenterology and Hepatology · 2026-06 · 24 (6) · 1550-1557
DOI: 10.1016/j.cgh.2025.10.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-06. Verfasst von Lindsey Creech und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Florida, Gainesville, Florida. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Gastroesophageal Reflux, Proton Pump Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Gastroesophageal reflux disease (GERD) is one of the most diagnosed diseases in the United States. A large proportion of patients have an inadequate response to proton pump inhibitors (PPIs), despite the optimization of dosing and timing. We hypothesized that such an inadequate response is often due to polymorphisms in cytochrome P450 2C19 (CYP2C19, CYP). This study aimed to assess the prevalence of rapid CYP metabolism in patients with GERD. METHODS: We conducted a single-center retrospective study on patients in an outpatient gastroenterology clinic with GERD who underwent CYP testing between 2019 and 2024. We collected data on CYP genotype, PPI dosing before and after CYP testing, endoscopy results, pH testing, and documentation of symptomatic improvement. Rapid and ultrarapid metabolizers were grouped as "rapid metabolizers," whereas normal and intermediate metabolizers were grouped as "normal metabolizers." RESULTS: In total, 421 patients with GERD who underwent CYP testing were included in the study. The prevalence of rapid metabolizers was 44% (n =184). The prevalence of Barrett's esophagus/erosive esophagitis was higher among ultrarapid metabolizers (24%; n = 5/21) than among normal metabolizers (7%; n = 12/165; odds ratio, 3.5; 95% confidence interval, 1.1-11.5; P = .0371). There was a nonstatistically significant trend towards higher odds of erosive esophagitis resolution when PPI was adjusted based on CYP results (odds ratio, 9.3; 95% confidence interval, 1.0-90; P = .081). CONCLUSIONS: A large proportion of patients with GERD who underwent CYP2C19 genotyping were rapid metabolizers of CYP2C19 and responded well to changing/adjusting PPIs accordingly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Florida, Gainesville, Florida.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Florida College of Medicine, Gainesville, Florida.
- School of Medicine, University of Florida, Gainesville, Florida.
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Florida College of Medicine, Gainesville, Florida. Electronic address: bqumseya@ufl.edu.
Zitieren
APA
Creech, L., King, W., Kleehammer, A. C., Zuercher, H., Pittman, K., Miquel-Chambers, C., Piranio, V., Iakovidis, A., Nguyen, K. A., & Qumseya, B. J. (2026). High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology, 24(6), 1550-1557. https://doi.org/10.1016/j.cgh.2025.10.021
Vancouver
Creech L, King W, Kleehammer AC, Zuercher H, Pittman K, Miquel-Chambers C, et al. High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology. 2026;24(6):1550-1557. doi:10.1016/j.cgh.2025.10.021
BibTeX
@article{Creech2026,
author = {Creech, Lindsey and King, William and Kleehammer, Andrew Chase and Zuercher, Hannah and Pittman, Katarina and Miquel-Chambers, Christopher and Piranio, Vincent and Iakovidis, Alexandria and Nguyen, Khoa Anh and Qumseya, Bashar J},
title = {High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {6},
pages = {1550--1557},
doi = {10.1016/j.cgh.2025.10.021}
}
EUVIMED